Skip to Main Content

In a big boost for its immunotherapy franchise, Merck (MRK)  disclosed top-line results of a key lung cancer study that showed its Keytruda treatment delivered particularly promising results. And while complete findings of the late-stage trial will not be known until the spring, the news is already reworking the outlook for the intensely competitive horse race among drug makers battling to dominate lung cancer.

So what did Merck say?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!